Hagop Kantarjian, MD of MD Anderson Cancer Center discusses the fact that no data for FLT3 inhibitor more effective than dirty inhibitor like Midostaurin in AML at the Scripps 36th Annual Conference: Clinical Hematology and Oncology in San Diego.
Hagop Kantarjian, MD of MD Anderson Cancer Center discusses the fact that no data for FLT3 inhibitor more effective than dirty inhibitor like Midostaurin in AML at the Scripps 36th Annual Conference: Clinical Hematology and Oncology in San Diego.